Search

Changes to Formulary as of 23rd May 2019:

 

BNF Category Number

Product/indication

Detail of change

2.12

Fibrates: first-line treatment not recommended

Added link to MHRA DSU

6.1.2.3

SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)

Added link to MHRA DSU

6.2.2

Carbimazole: risk of acute pancreatitis

Added link to MHRA DSU

6.2.2

Carbimazole: increased risk of congenital malformations; strengthened advice on contraception

Added link to MHRA DSU

8.1.5

Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events

Added link to MHRA DSU

5.1.12

Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects

Added link to MHRA DSU

 10.1.3

Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials

Added link to MHRA DSU

 4

Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme

Added link to MHRA DSU

 14.4

Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older

Added link to MHRA DSU

 9.5

Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy

Added link to MHRA DSU

 1.5.3 & 10.1.3

Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing

Added link to MHRA DSU

 8.2

Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements

Added link to MHRA DSU

8

 

Added link to NICE NG122

5

 

Added link to NICE NG120

6.1.2.3

Ertugliflozin

Added as GREEN ALT drug and added link to NICE TA572

8.1.5

Brigatinib

Added as RED drug and added link to NICE TA571

8.1.5

Pembrolizumab

Added link to NICE TA570

8.1.5

Pertuzumab

Added link to NICE TA569

10.1.3

Abatacept 

Added link to NICE TA568

8.1.5

Tisagenlecleucel

Added link to NICE TA567

3.4.2

Benralizumab

Added as RED drug and added link to NICE TA565

8.1.5

Dabrafenib

Added link to NICE TA564

8.1.5

Abemaciclib

Added as RED drug and added link to NICE TA563

8.1.5

Encorafenib

Added as RED drug and added link to NICE TA562

8.1.5

Venetoclax

Added link to NICE TA561

8.1.5

Bevacizumab

Added link to NICE TA560

6.1.6

Freestyle Libre

Changed from RED to GREEN+

1.9.4

Pancrex V Capsules

Added as a GREEN+ drug

2.3.2 & 4.7.3

Mexiletine

Added as NOT APPROVED for cardiac arrthymias and pain (i.e. unlicensed uses)

2.5.1

Minoxidil for hypertension

Changed from RED to GREEN

4.9.1

Ropinirole for restless legs

Added as a GREEN drug

4.9.1

Pramipexole for restless legs

Added as a GREEN drug

6.5.1.3

Ovitrelle® injection

Added as RED drug

15.1.2

Methoxyflurane (Penthrox®)

Added as RED drug

7.3.2.3

Jaydess

Deleted from formulary

7.3.2.3

Kyleena

Added as a GREEN drug